Prognosis and incidence of immunological and oncological complications after direct-acting antiviral therapy for chronic hepatitis C.
暂无分享,去创建一个
S. Saito | A. Naganuma | T. Uraoka | Y. Shimada | T. Nagashima | T. Ueno | H. Nakajima | Y. Kanayama | H. Takagi | D. Uehara | S. Takakusagi | M. Shibasaki | T. Kohga | K. Sato
[1] S. Wongkham,et al. Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication. , 2020, Canadian journal of diabetes.
[2] M. Kudelka,et al. Revealed heterogeneity in rheumatoid arthritis based on multivariate innate signature analysis. , 2020, Clinical and experimental rheumatology.
[3] S. Toyama,et al. Effectiveness and safety of chronic hepatitis C treatment with direct-acting antivirals in patients with rheumatic diseases: A case-series , 2019, Modern rheumatology.
[4] P. Messa,et al. Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence , 2019, Pathogens.
[5] G. Nassar,et al. Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection , 2019, Journal of Gastrointestinal Cancer.
[6] B. Obrișcă,et al. Clinical outcome of HCV-associated cryoglobulinemic glomerulonephritis following treatment with direct acting antiviral agents: a case-based review , 2019, Clinical Rheumatology.
[7] A. Singal,et al. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. , 2019, Gastroenterology.
[8] H. Okamoto,et al. Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature , 2019, World journal of clinical cases.
[9] N. Ferrara,et al. VEGF in Signaling and Disease: Beyond Discovery and Development , 2019, Cell.
[10] G. Ioannou,et al. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection? , 2019, Gastroenterology.
[11] M. Goicoechea,et al. Mixed cryoglobulinaemia vasculitis after sustained hepatitis C virological response with direct-acting antivirals , 2018, Clinical kidney journal.
[12] A. Albillos,et al. HCV‐positive lymphoma after sustained virological response with direct‐acting antiviral agents: The game is not over after HCV eradication , 2018, Journal of viral hepatitis.
[13] A. Anderson,et al. What are the dominant cytokines in early rheumatoid arthritis? , 2017, Current opinion in rheumatology.
[14] J. Khoury,et al. Is There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies? , 2017, Journal of clinical gastroenterology.
[15] Mihran V. Naljayan,et al. MPGN and mixed cryoglobulinemia in a patient with hepatitis C – new treatment implications and renal outcomes , 2017, Clinical nephrology. Case studies.
[16] M. Gale,et al. Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy , 2017, PloS one.
[17] P. Corstjens,et al. THU0042 Longitudinal IP-10 serum levels associate with the course of disease activity and achieving dmard-free sustained remission in rheumatoid arthritis , 2017 .
[18] P. Merkel,et al. New-onset hepatitis C virus-associated glomerulonephritis following sustained virologic response with direct-acting antiviral therapy . , 2017, Clinical nephrology.
[19] H. Tomita,et al. Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report , 2017, BMC Nephrology.
[20] A. Facciorusso,et al. DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment , 2016, PloS one.
[21] R. Colvin,et al. Lupus-Like Immune Complex-Mediated Glomerulonephritis in Patients With Hepatitis C Virus Infection Treated With Oral, Interferon-Free, Direct-Acting Antiviral Therapy , 2016, Kidney international reports.
[22] M. Stepanova,et al. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. , 2016, Gastroenterology.
[23] T. Liang,et al. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. , 2015, Gastroenterology.
[24] L. Prokunina-Olsson,et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. , 2014, The Journal of clinical investigation.
[25] M. Murad,et al. Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis , 2013, The American Journal of Gastroenterology.
[26] M. Dehghani,et al. Systematic Review and Meta-analysis of Insulin Therapy and Risk of Cancer , 2012, Hormones and Cancer.
[27] Alexandra G. Smith,et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network , 2011, British Journal of Cancer.
[28] G. Reeves,et al. The influence of hepatitis C infection and interferon-α therapy on thyrotropin blocking and stimulating autoantibodies in Graves' ophthalmopathy: a case report , 2009, Thyroid research.
[29] S. Gabriel,et al. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases , 2009, Arthritis research & therapy.
[30] K. McGlynn,et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. , 2005, Gastroenterology.
[31] S. Kubo,et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma , 2004, Cancer Science.